Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
Saba Capital Releases Presentation Outlining Its Plan to Deliver Substantial Liquidity and Long-Term Returns at Seven U.K. Trusts
Details the Need for Shareholder-Driven Change Due to the Trusts’ Significant Discounts…
Saba Capital Shares Key Facts Demonstrating the Need for Shareholder-Driven Change at Seven U.K. Trusts
Read the Truth About Saba’s Track Record, Objectives, Nominees and Plan to…